Addiction treatment and substance use disorder (SUD) M&A activity accelerated sharply through 2025 and into 2026. After a multi-year reset following the late-2010s lab-billing and out-of-network billing scandals — and the COVID-era operating disruption — the sector has emerged with cleaner platforms, more disciplined operators, and renewed buyer appetite.
For owners of MAT clinics, residential treatment programs, intensive outpatient (IOP), partial hospitalization (PHP), and dual-diagnosis programs, 2026 represents a meaningful exit window. This guide covers what sellers should know.
Why Addiction Treatment M&A Is Active in 2026
Three structural forces are driving deal flow:
1. Demand fundamentals.
Opioid use disorder, alcohol use disorder, and stimulant use disorder all remain at elevated levels post-pandemic. Demand for treatment outpaces supply in most markets. Payer coverage has expanded under parity legislation and Medicaid expansion.
2. Cleaner industry post-reset.
The 2017–2020 enforcement wave on lab billing, out-of-network billing, and patient brokering forced bad actors out and clarified compliance norms. Buyers can now underwrite SUD platforms with materially less compliance risk than a decade ago.
3. PE platforms in scale-up mode.
Behavioral health and SUD have become a defined PE thesis with multiple platforms in active build mode. These platforms are aggressive add-on acquirers, creating consistent demand for tuck-in opportunities.
Sub-Sector Valuation Ranges (Q2 2026)
| Asset Type | EBITDA Size | Typical Multiple Range |
|---|
| MAT outpatient platform (multi-site) | $5M+ | 10x–14x |
| MAT outpatient (single-state, multi-site) | $2M–$5M | 8x–11x |
| MAT outpatient (single-site) | sub-$2M | 5x–8x |
| Residential treatment (premium private pay) | $3M+ | 9x–13x |
| Residential treatment (mixed payer) | $2M–$5M | 7x–10x |
| IOP / PHP outpatient programs | $1M–$5M | 7x–11x |
| Detox + residential continuum | $5M+ | 10x–13x |
| Dual-diagnosis (SUD + mental health) | $3M+ | 9x–13x |
| Multi-state SUD platform | $10M+ | 12x–15x+ |
Premiums apply for: diversified payer mix, in-network commercial contracts at favorable rates, demonstrated outcomes data, accreditation (Joint Commission or CARF), strong clinician retention, and clean compliance history.
Payer Mix and Valuation
Payer mix is the single largest valuation variable in SUD M&A. Buyer underwriting differs sharply across payer profiles.
Private Pay
- Highest per-episode revenue and margin
- Concentration risk if dependent on a single referral channel
- Buyers value diversified marketing, repeatable patient acquisition economics, and ethical referral practices
Commercial Insurance (In-Network)
- Increasingly the dominant model post-out-of-network reset
- Buyers scrutinize contract rates, contract durations, in-network vs. out-of-network mix history, and authorization-to-billing efficiency
- In-network platforms with strong rates and durable contracts trade at premium multiples
Commercial Insurance (Out-of-Network)
- Significantly discounted by buyers
- Compliance risk perceived as elevated
- Surprise Billing Act exposure
- Rarely supports premium multiples in 2026
Medicaid
- Lower margins but more stable demand
- Important access platforms; valued differently in mission-aligned PE
- State-specific rate environments matter materially
- MAT-focused Medicaid platforms can earn solid multiples on recurring revenue
Block Grant / SAMHSA Funded
- Public-payer dependent
- Stable but capped revenue
- Discounted by mainstream PE; valued by mission-aligned buyers
Service Line Considerations
MAT (Medication-Assisted Treatment) Outpatient
- Typically buprenorphine, methadone (OTPs), or naltrexone-based
- DEA registration and SAMHSA OTP certification (where applicable) are foundational
- Telehealth flexibility post-COVID has expanded access models — buyer underwriting increasingly weighs hybrid telehealth + in-person economics
- Recurring monthly visit revenue produces SaaS-like financial profile that PE values
Residential Treatment (RTC)
- Higher revenue per episode but higher fixed cost
- Length-of-stay distribution and clinical justification documentation are key diligence items
- Real estate ownership vs. lease structure materially affects valuation
- Geographic concentration of beds drives buyer interest
IOP / PHP Outpatient
- Lower facility intensity, higher patient volume
- Strong PE platform demand for tuck-in
- Multi-site IOP/PHP platforms in growing metros are particularly attractive
Detox / Withdrawal Management
- Highly regulated, often combined with residential
- Buyer caution on standalone detox; valued more highly when integrated with continuum
Dual-Diagnosis / Co-Occurring (SUD + Mental Health)
- Premium multiples for true dual-diagnosis capability
- Increasingly the standard of care; non-dual-diagnosis programs face structural pressure
The Most Active Addiction Treatment Buyers in 2026
Strategic Acquirers
- Acadia Healthcare (NASDAQ: ACHC) — large strategic acquirer in behavioral health and SUD
- Universal Health Services / UHS Behavioral (NYSE: UHS) — selective behavioral health and SUD acquisitions
- Behavioral Health Group — MAT platform, active acquirer
- Pinnacle Treatment Centers — residential and outpatient SUD
- Discovery Behavioral Health — multi-modality behavioral health
- Recovery Centers of America (RCA) — residential SUD
- Eating Recovery Center / Pathlight Mood & Anxiety Center (where SUD overlaps)
- CleanSlate Outpatient Addiction Medicine — MAT-focused
- Crossroads Treatment Centers — MAT-focused, active in multiple states
- Vistria Group portfolio in behavioral health and SUD
- Charlesbank Capital Partners portfolio
- Linden Capital Partners — healthcare-only PE active in SUD
- Webster Equity Partners portfolio
- Bain Capital Double Impact — mission-aligned investment
- Cressey & Company — healthcare services PE
- Tenex Capital Management — healthcare services
- NMS Capital — healthcare services
- Multiple independent sponsors focused on behavioral health and SUD
- Family offices with healthcare allocations
A well-curated buyer list for an SUD seller typically includes 12–25 firms across these categories — selected based on the seller’s specific service mix, payer profile, and geography.
Diligence Items Unique to SUD M&A
Buyer diligence in addiction treatment is more intensive than in most healthcare services M&A. Expect deep scrutiny of:
Regulatory and Compliance
- DEA registration and Schedule II/III/IV/V controlled substance handling
- SAMHSA Opioid Treatment Program (OTP) certification (for methadone)
- State licensure across all sites
- Accreditation (Joint Commission BHC or CARF)
- Joint Commission / CARF survey history
- Patient brokering / Eddy Act exposure (particularly for residential)
- Lab billing compliance — historical and ongoing
- Out-of-network billing history
- Surprise Billing Act compliance
- Patient consent and confidentiality (42 CFR Part 2)
Payer Contract Integrity
- Contract rate review by payer
- In-network vs. out-of-network history
- Authorization-to-billing match analysis
- Recoupment and audit history
Clinical and Outcomes
- Length-of-stay distribution and clinical justification
- Outcomes documentation and measurement methodology
- Discharge against medical advice (AMA) rates
- Readmission and post-treatment engagement
Workforce
- Clinician licensure verification
- Clinician turnover and tenure
- Counselor and tech turnover
- Wage-and-hour exposure
Real Estate
- Owned vs. leased facility analysis
- Bed capacity and utilization
- Zoning and conditional use permitting
Marketing and Patient Acquisition
- Marketing spend efficiency and per-admission cost
- Referral source diversity
- Online lead-generation compliance (LegitScript certification, advertising compliance)
Deal Structures Common in SUD M&A
Equity Rollover
- Increasingly the norm for founder-led platforms
- Typical rollover: 15–35% of equity value
- Reflects buyer desire for founder alignment and bridges valuation gaps
Earnout
- Common for SUD given outcome and growth uncertainty
- Typically 10–25% of total consideration
- Tied to revenue, EBITDA, or census metrics over 1–3 years
- Sellers should negotiate earnout protection language carefully
Real Estate Carve-Out
- For residential platforms, the operating company often sells while the real estate is retained by the seller and leased to the buyer
- Produces tax efficiency and ongoing income for the seller
Working Capital Adjustment
- Standard mechanism; particular focus on patient A/R aging and authorization-to-payment lag
Common SUD Seller Mistakes
1. Single-buyer conversations.
The active SUD buyer pool is broader than most owners realize. Single-buyer conversations consistently leave value on the table.
2. Underestimating compliance diligence.
Sellers without a clean compliance house in order routinely face material price reductions during diligence. Pre-sale compliance review is essential.
3. Not reconciling lab billing history.
Even programs that have moved away from aggressive lab billing face buyer scrutiny of historical practices. Clear documentation of historical practices and current compliance posture is required.
4. Presenting out-of-network financials as run-rate.
Buyers will not underwrite out-of-network revenue at full credit. Sellers must present in-network forward run-rate clearly.
5. Neglecting outcomes documentation.
Buyers increasingly require evidence of clinical outcomes. Programs that can document outcomes credibly trade at premium multiples.
The 12–24 months before sale are when SUD platforms most successfully build value.
Operationally:
- Migrate out-of-network revenue to in-network where possible
- Negotiate or renegotiate commercial contracts
- Build outcomes measurement and documentation
- Reduce clinician turnover; document retention initiatives
- Diversify referral sources
- Address compliance gaps (particularly DEA, SAMHSA, lab billing)
Financially:
- Sell-side Quality of Earnings
- Detailed payer mix and rate analysis
- Working capital benchmarking
- EBITDA add-back documentation
Legally:
- Compliance audit by SUD-specialized healthcare counsel
- Patient consent and 42 CFR Part 2 review
- Marketing compliance review (LegitScript, etc.)
How Hendon Partners Helps SUD Sellers
Hendon Partners advises owners of MAT, residential, IOP, PHP, and dual-diagnosis platforms through preparation, sale process, and close. Our buyer network includes the strategic acquirers and PE platforms most active in SUD M&A in 2026 — and our process design is calibrated to the specific compliance, payer, and operational dynamics of behavioral health.
For SUD platforms with $1M+ EBITDA, a structured competitive process consistently delivers materially better outcomes than unrepresented sales — both in headline price and in deal structure protection.
Schedule a confidential SUD-focused conversation with Hendon Partners →
Hendon Partners is a sell-side only M&A advisory firm with deep expertise in behavioral health and addiction treatment transactions. We advise owners of MAT, residential, IOP, PHP, dual-diagnosis, and detox programs across the United States.
